Invokana, Farxiga, Jardiance Get Ketoacidosis, Urinary Tract Infection Warnings

(December 21, 2015, 12:00 PM EST) -- SILVER SPRING, Md. — The Food and Drug Administration on Dec. 4 said a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors has resulted in new label warnings about the risk of excess acid in the blood and of serious urinary tract infections, both of which can result in hospitalization.

Drugs that must carry the new warnings includes Invokana brand canagliflozin, Farxiga brand dapaglifozin and Jardiance brand empagliflozin.

The FDA said patients should stop taking the drugs and seek immediate medical attention if they have symptoms of...
To view the full article, register now.